The stock price of a domestic bio company declined after the clinical trial for a new drug candidate that had been out-licensed overseas was halted. As the related contract has been terminated, the candidate is expected to be returned. The company will also find it difficult to receive additional milestone payments that could have been earned depending on future development achievements. However, it is reported that the upfront payment already received will not need to be returned. The company plans to review whether to proceed with further development of the returned candidate. In addition, another candidate from the company recently received approval for a clinical trial in the United States, making it necessary to track the progress of each research project.


Credit and margin traders observing the company’s future development direction may need to reorganize their asset management schedules along with their holding plans. Checking the maturity dates and actual interest rates of prior transactions can help understand the current financial structure. Credit and margin refinancing services can be considered as an option by comparing the ongoing transaction terms, interest rates, and repayment methods. Comparing usage costs according to the expected holding period enables investors to choose the operating method that best suits their investment goals.

Termination of Bio Out-Licensing Agreement... How to Secure Investment Capacity Through Credit and Margin Repayment View original image

Meanwhile, interest in stock loans continues to rise, as more investors turn to stock loans to leverage greater funds for stock purchases and avoid missing investment opportunities.


Another advantage of stock loans is that even if margin or credit users face the risk of forced liquidation due to a sharp stock price drop, they can simply switch over without providing additional collateral or selling stocks, and then wait for a rebound.


◆ AllNewStockLoan launches a product with the lowest annual interest rate in the industry at 5%!

AllNewStockLoan has launched a securities-linked credit product that allows all investors to experience stock loans at an industry-low interest rate in the 5% range. The product can be used not only for stock purchases but also for refinancing margin/credit with securities firms, and it can be leveraged up to four times including self-capital, regardless of credit rating. In addition, investors using the alternative trading system (NXT) can also take advantage of this service.


If you would like to know more about AllNewStockLoan, you can contact the customer service center (☎1599-8666) to conveniently speak with a professional advisor at any time, regardless of your loan approval status.


○ Industry-low interest rate product in the 5% range launched!

○ ETF trading available

○ Stock funds can be leveraged up to four times! (Including personal capital)

○ Immediate same-day refinancing of securities margin/credit available!

○ Alternative trading system (NXT) supported

○ Even stocks difficult to purchase with existing securities firm credit or stock loans are now OK!

* AllNewStockLoan customer service center: 1599-8666

Go to: https://allnewstockloan.co.kr


Neosapience, SkyLabs, Orum Therapeutics, Wooree Technology, JNTC



※ The above content is unrelated to the editorial direction of The Asia Business Daily, and all responsibility lies with the information provider.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing